Scilex to present poster on ELYXYB at AHS meeting

Scilex announced it will be presenting a poster on ELYXYB at the 66th Annual Scientific Meeting of the American Headache Society, AHS, to be held in San Diego, CA on June 13-16, 2024. The poster presentation will describe the efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post hoc analysis of two Phase 3 randomized clinical trials. Key highlights of the ELYXYB presentation: Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post-hoc analysis of two Phase 3 randomized clinical trials. In a post-hoc analysis of two Phase 3 randomized clinical trials, the efficacy of ELYXYB was compared with placebo in patients who were previously treated with triptans. In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB-treated arm achieved 2-hour pain freedom than placebo. The likelihood of achieving pain freedom was 200% greater with ELYXYB than with placebo.